MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy
Aim: MET exon 14 (METex14) skipping occurs in 3–4% of non-small-cell lung cancer (NSCLC) cases. Low frequency of this alteration necessitated open-label, single-arm trials to investigate MET inhibitors. Since broad MET biomarker testing was only recently introduced in many countries, there is a la...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2025-01-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584184869158912 |
|---|---|
| author | Michael Thomas Petros Christopoulos Wade T Iams Julien Mazieres Alexis B Cortot Nir Peled Gabriele Minuti Egbert F Smit Francois Audhuy Karin Berghoff S Peter Eggleton Frank Fries Maike Hildenbrand Peter Liu Seyed Hamidreza Mahmoudpour Christoph Menzel Dina Oksen |
| author_facet | Michael Thomas Petros Christopoulos Wade T Iams Julien Mazieres Alexis B Cortot Nir Peled Gabriele Minuti Egbert F Smit Francois Audhuy Karin Berghoff S Peter Eggleton Frank Fries Maike Hildenbrand Peter Liu Seyed Hamidreza Mahmoudpour Christoph Menzel Dina Oksen |
| author_sort | Michael Thomas |
| collection | DOAJ |
| description | Aim: MET exon 14 (METex14) skipping occurs in 3–4% of non-small-cell lung cancer (NSCLC) cases. Low
frequency of this alteration necessitated open-label, single-arm trials to investigate MET inhibitors. Since
broad MET biomarker testing was only recently introduced in many countries, there is a lack of historical
real-world data from patients with METex14 skipping NSCLC receiving conventional therapies. Given
the rarity of this population and limitations of existing real-world data sources, the MOMENT registry
aims to prospectively collect uniform, comprehensive, high-quality data from patients with METex14
skipping advanced NSCLC treated in routine clinical practice, which can support clinical and regulatory
decision making. Patients & methods: MOMENT is a multinational, non-interventional disease registry
collecting data on patients with METex14 skipping advanced NSCLC receiving any systemic anticancer
therapy. Newly diagnosed patients and those already receiving treatment are eligible. Patients with
previous participation in a clinical trial can be included if they receive at least one subsequent therapy
line in a routine clinical setting. Eligible systemic treatment includes all available anticancer therapies
(approved, conditionally approved or provided through Early Access). Data collection includes biomarker
testing results, demographics, baseline clinical characteristics, treatment details and effectiveness, safety
information and imaging. Registry site inclusion is dependent on confirmation that local METex14
skipping detectionmethods are sufficient to confirm METex14 skipping status.MOMENT is currently active
at more than 60 sites across Europe and North America and approximately 700 patients are expected to
be enrolled within the next 4 years. The first patient was enrolled on 4 October 2022. After completion of
data collection, MOMENT data can be shared with external parties to conduct non-interventional studies.
Discussion/conclusion: The MOMENT registry collects comprehensive, high-quality real-world data from
patients with METex14 skipping advanced NSCLC receiving systemic anticancer treatment in a routine
clinical setting, to enable future studies informing regulatory decisions and optimal care for this rare
population. |
| format | Article |
| id | doaj-art-7fcf75fc05e34924a08008a6c9f480eb |
| institution | Kabale University |
| issn | 2042-6313 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Becaris Publishing Limited |
| record_format | Article |
| series | Journal of Comparative Effectiveness Research |
| spelling | doaj-art-7fcf75fc05e34924a08008a6c9f480eb2025-01-27T15:14:32ZengBecaris Publishing LimitedJournal of Comparative Effectiveness Research2042-63132025-01-0114210.57264/cer-2024-0127MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapyMichael Thomas0Petros Christopoulos1Wade T Iams2Julien Mazieres3Alexis B Cortot4Nir Peled5Gabriele Minuti6Egbert F Smit7Francois Audhuy8Karin Berghoff9S Peter Eggleton10Frank Fries11Maike Hildenbrand12Peter Liu13Seyed Hamidreza Mahmoudpour14Christoph Menzel15Dina Oksen16Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital & National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ & Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, GermanyDepartment of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital & National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ & Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, GermanyDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USACHU de Toulouse, Universite´ Paul Sabatier, Toulouse, FranceUniversite de Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020 – UMR-S 1277 – Canther, F-59000 Lille, FranceHelmsely Cancer Center, Shaare Zedek Medical Center, Jerusalem, IsraelClinical Trial Center: Phase 1 & Precision Medicine, IRCCS, Regina Elena National Cancer Institute, 00144, Rome, ItalyDepartment of Pulmonary Diseases, Leiden University Medical Centre, Leiden, The NetherlandsMerck Serono S.A.S., Lyon, France, an affiliate of Merck KGaAGlobal Patient Safety, Merck Healthcare KGaA, Darmstadt, GermanyGlobal Clinical Development, Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaAData Monitoring Management & Innovation, Merck Healthcare KGaA, Darmstadt, GermanyCompanion Diagnostics & Biomarker Strategy, Merck Healthcare KGaA, Darmstadt, GermanyGlobal Development Operations, Merck Serono Pharmaceutical R&D Co., Ltd., Beijing, China, an affiliate of Merck KGaADepartment of Epidemiology, Merck Healthcare KGaA, Darmstadt, GermanyCompanion Diagnostics & Biomarker Strategy, Merck Healthcare KGaA, Darmstadt, GermanyDepartment of Epidemiology, Merck Healthcare KGaA, Darmstadt, GermanyAim: MET exon 14 (METex14) skipping occurs in 3–4% of non-small-cell lung cancer (NSCLC) cases. Low frequency of this alteration necessitated open-label, single-arm trials to investigate MET inhibitors. Since broad MET biomarker testing was only recently introduced in many countries, there is a lack of historical real-world data from patients with METex14 skipping NSCLC receiving conventional therapies. Given the rarity of this population and limitations of existing real-world data sources, the MOMENT registry aims to prospectively collect uniform, comprehensive, high-quality data from patients with METex14 skipping advanced NSCLC treated in routine clinical practice, which can support clinical and regulatory decision making. Patients & methods: MOMENT is a multinational, non-interventional disease registry collecting data on patients with METex14 skipping advanced NSCLC receiving any systemic anticancer therapy. Newly diagnosed patients and those already receiving treatment are eligible. Patients with previous participation in a clinical trial can be included if they receive at least one subsequent therapy line in a routine clinical setting. Eligible systemic treatment includes all available anticancer therapies (approved, conditionally approved or provided through Early Access). Data collection includes biomarker testing results, demographics, baseline clinical characteristics, treatment details and effectiveness, safety information and imaging. Registry site inclusion is dependent on confirmation that local METex14 skipping detectionmethods are sufficient to confirm METex14 skipping status.MOMENT is currently active at more than 60 sites across Europe and North America and approximately 700 patients are expected to be enrolled within the next 4 years. The first patient was enrolled on 4 October 2022. After completion of data collection, MOMENT data can be shared with external parties to conduct non-interventional studies. Discussion/conclusion: The MOMENT registry collects comprehensive, high-quality real-world data from patients with METex14 skipping advanced NSCLC receiving systemic anticancer treatment in a routine clinical setting, to enable future studies informing regulatory decisions and optimal care for this rare population.cancer registrymetex14 skippingnsclcreal-world datatargeted therapy |
| spellingShingle | Michael Thomas Petros Christopoulos Wade T Iams Julien Mazieres Alexis B Cortot Nir Peled Gabriele Minuti Egbert F Smit Francois Audhuy Karin Berghoff S Peter Eggleton Frank Fries Maike Hildenbrand Peter Liu Seyed Hamidreza Mahmoudpour Christoph Menzel Dina Oksen MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy Journal of Comparative Effectiveness Research cancer registry metex14 skipping nsclc real-world data targeted therapy |
| title | MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy |
| title_full | MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy |
| title_fullStr | MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy |
| title_full_unstemmed | MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy |
| title_short | MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy |
| title_sort | moment registry patients with advanced non small cell lung cancer harboring met exon 14 skipping treated with systemic therapy |
| topic | cancer registry metex14 skipping nsclc real-world data targeted therapy |
| work_keys_str_mv | AT michaelthomas momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT petroschristopoulos momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT wadetiams momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT julienmazieres momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT alexisbcortot momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT nirpeled momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT gabrieleminuti momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT egbertfsmit momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT francoisaudhuy momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT karinberghoff momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT spetereggleton momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT frankfries momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT maikehildenbrand momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT peterliu momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT seyedhamidrezamahmoudpour momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT christophmenzel momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy AT dinaoksen momentregistrypatientswithadvancednonsmallcelllungcancerharboringmetexon14skippingtreatedwithsystemictherapy |